水飞蓟宾联合恩替卡韦治疗乙型病毒性肝炎肝硬化的疗效观察.

OBJECTIVE: To probe into the clinical efficacy of silibinin combined with entecavir in treatment of liver cirrhosis of hepatitis B. METHODS: 72 patients with liver cirrhosis of hepatitis B admitted into Ningxia People’s Hospital from Jan. 2016 to Jan. 2017 were selected and divided into observation group and control group via random number table, with 36 cases in each. The control group was treated with entecavir, while the observation group was given silibinin based on the control group. The liver function indicators, liver fibrosis indicators and incidence of adverse drug reactions of two groups were observed. RESULTS: After treatment, levels of alanine aminotransferase, prothrombin time, serum total bilirubin and albumin ol two groups were better than those of before treatment, and the observation group was better than the control group, with statistical significance (P <0.05). After treatment, the hyaluronic acid, type IV procollagen and type HI procollagen levels were better than those of before treatment, and the observation group was better than the control group, with statistical significance(P <0. 05). The incidence of adverse drug reactions of observation group was 11. 12% (4/36), significantly lower than that of control group [30.58% (1 1/36) ], with statistical significance(P <0. 05). CONCLUSIONS: The efficacy of silibinin combined with entecavir in treatment of liver cirrhosis of hepatitis B is remarkable, which can effectively improve levels of liver function indicators and liver fibrosis indicators with fewer adverse drug reactions. [ABSTRACT FROM AUTHOR]